New research has discovered a link between changes in the function and shape of immune cells, mechanical changes in blood cells and persistent depressive disorders. Depressive disorders are one of the primary causes of disability around the globe. Depression is known to cause an increase in the production of stress hormones, including glucocorticoids, as well as cause chronic low-grade inflammation. These effects can interfere with immune cell structure.
Persistent depressive disorder can impact an individual for a lifetime and is known to last for at least two years. The eye-opening study was carried out by Dr. Andreas Walther while working with TU Dresden’s Chair of biopsychology, Clemens Kirschbaum. Dr. Walther, who is the study’s lead author, has noted that it is important to advance psychological and biological therapies to help understand and treat depressive disorders more sustainably and efficiently in the long term.
The scientists carried out a cross-sectional, case-control study using a test to determine the ability of a cell to alter its shape based on changes in images of blood cells. They used blood samples obtained from healthy individuals. The study included 70 healthy controls and 69 individuals who had a heightened risk for depressive disorders.
Each participant underwent clinical evaluation using the Composite International Diagnostic Interview. This internationally recognized clinical interview process is usually used to diagnose mental health disorders. The researchers then used an AI deep-learning technique to scan more than 16 million images of blood cells. These images were categorized into the primary types of blood cells and measured using parameters such as size of the cell as well as their ability to alter their shapes.
The researchers found that in comparison to cells in the control subjects, neutrophils, lymphocytes and monocytes were deformable in patients suffering from persistent depressive disorder. Monocytes/macrophages, neutrophils and lymphocytes are types of white blood cells that make up the immune system.
Dr. Jean Kim, an assistant psychiatry professor, was consulted about the study’s discovery. Kim stated that the findings suggest that deformability of blood cells was a marker of altered states of immune cells, which correlates with immune hyperactivity vs. hypoactivity. She noted that more studies needed to be conducted to understand the wider implications of depressive disorder on the immune system.
This study was conducted in collaboration with researchers from Switzerland’s University of Zurich, the Max-Planck-ZentrumfürPhysik und Medizin Erlangen in Germany, the Max Planck Institutes for the Science of Light and the Technische Universität Dresden (TU Dresden). Study findings were published in the “Translational Psychiatry” journal.
It is fortunate that companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are working toward bringing to market psychedelic therapies targeting neurological indications, including major depression, PTSD and other such illnesses. These treatments could get the mental health crisis under control, or at least put the brakes on its proliferation.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…